Trial Profile

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients with Symptomatic Generalized Myasthenia Gravis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Aug 2025 According to Regeneron Pharmaceuticals media release, detailed results from the NIMBLE trial will be presented at an upcoming medical meeting.
26 Aug 2025 According to Regeneron Pharmaceuticals media release, Primary endpoint has been met. (Change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score)
26 Aug 2025 According to Regeneron Pharmaceuticals media release, U.S. regulatory submission for cemdisiran monotherapy is planned for the first quarter of 2026, pending discussions with the FDA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com